Webinar: 3rd Bio-Techne Targeted Protein Degradation Symposium

Now Available On-Demand!

This free half-day symposium covers some of the hottest science from the exciting field of TPD and includes talks on anti-viral PROTACs, a clinical candidate Degrader of BRD9, the BromoTag^® degradation platform, degraders targeting the CBP/p300 lysine acetyltransferases, new cereblon-recruiting warheads for PROTAC^® design and the first public presentation of the new CoraFluor TR-FRET probes for TPD assays.

		Welcome and Introduction Dr. Hannah Maple Innovation Manager, Bio-Techne
		Targeted Protein Degradation as an Antiviral Strategy Prof. Priscilla Yang Professor, Stanford University

		Strategies to Chemically Modulate Enhancers: Degraders of the CBP/p300 Lysine Acetyltransferases Dr. Christopher Ott Assistant Professor and Director, MGH Center for Molecular Therapeutics, Harvard Medical School
		Development of BromoTAG: A New Ligand Inducible Degron System Adam Bond PhD candidate, Centre for Targeted Protein Degradation - University of Dundee Dr. Conner Craigon PDRA, Ciulli Lab, Centre for Targeted Protein Degradation - University of Dundee
		Just Wait for It – CoraFluor-Enabled TR-FRET Assay Strategies for Facile PROTAC Profiling Dr. Ralph Mazitschek Assistant Professor, Harvard Medical School
		Here is Why We Use Phenyl Glutarimide (PG) as an Alternative Cereblon-Directing Warhead for PROTACs Dr. Zoran Rankovic Director, CBT Chemistry Centers, St. Jude Children’s Research Hospital
		The Discovery and Characterization of CFT8634: A Potent and Selective Degrader of BRD9 for the Treatment of SMARCB1-Perturbed Cancers Dr. Kate Jackson Senior Director of Chemistry, C4 Therapeutics
		Closing Remarks Dr. Joel Cresser-Brown Senior Product Specialist, Bio-Techne